News
WHIS 2025: Driving the future of women’s health
As we all know too well, for decades, women’s health has been an overlooked corner of medicine.
Research has often excluded women, leading to gaps in understanding, and funding has lagged behind other areas of healthcare.
Yet in recent years, a quiet revolution has been taking shape.
Startups, clinicians, and investors have begun to focus on conditions that affect half the population, from endometriosis to menopause, fertility to cardiovascular disease.
The result is a wave of innovation but one that faces challenges in scaling and adoption without stronger collaboration across the healthcare system.
That is where WHIS (Women’s Health Innovation Summit) comes in.
Now in its seventh year, the gathering has become a rare forum that spans the full breadth of women’s health.
It brings together payers, providers, big pharma, consumer health companies, digital health innovators, investors, and early-stage startups under one roof.
The idea is simple: progress in women’s health requires everyone in the chain—from research to delivery of care—to share knowledge and align on priorities.
This year, the summit has expanded its focus on payers and providers. Their presence is crucial.
New ideas and technologies only have impact if they can find their way into the complex realities of healthcare delivery and reimbursement.
By including those voices more prominently, the event aims to make sure that conversations about innovation are grounded in practical pathways to adoption.
It is an acknowledgment that good science alone is not enough; systems and incentives must also evolve to meet the needs of women.
The programme reflects the diversity of perspectives shaping the field.
Leaders from Kaiser Permanente, IVI RMA Global, McKinsey & Company, Maven Clinic, and Kindbody are set to share insights, covering everything from reproductive medicine to digital platforms and strategy.
They will be joined by representatives from Mass General Brigham, Beckman Coulter, Eli Lilly, Kimberly-Clark, and CVS Health, each bringing experience from different corners of healthcare and life sciences.
Alongside them, early-stage companies will present technologies that could redefine diagnostics, therapeutics, and medical devices for women’s health.
What makes WHIS particularly significant is the way it spotlights both the structural challenges and the opportunities for transformation.
Women’s health has long suffered from fragmented approaches, where reproductive issues were siloed from broader conversations about chronic disease, mental health, or ageing.
The summit underscores the reality that women’s health is not a niche, but a spectrum that intersects with every stage of life and every part of the healthcare system.
For attendees, the event is less about promotion and more about building the relationships and strategies needed to change how women’s health is treated, funded, and prioritised.
It is a space where clinicians can meet entrepreneurs, where established players can learn from nimble startups, and where investors can better understand the long-term value of supporting women’s health innovation.
The conversations that begin here have the potential to ripple far beyond the conference walls.
As the summit enters its seventh year, it stands as both a marker of progress and a reminder of how much work remains.
Women’s health has momentum but ensuring that momentum translates into impact requires sustained commitment across science, business, and policy.
WHIS offers a chance to take part in that effort.
Registration is now open, with super early bird pricing available until Friday, 22 August. You can register here
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







